The agreement will leverage SciNeuro’s proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market. Both companies
The application sought approval for Ebvallo as monotherapy in adult and paediatric patients aged two years and above with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have
The facility forms a key component of the company’s $23bn US investment programme, first outlined in April 2025, and aims to enhance the supply of RLT cancer treatments
Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m. Additional development, regulatory, and commercial milestone payments are included in the deal, along with tiered
Through this partnership, Takeda aims to enhance patient care while exploring new opportunities for vedolizumab. Marketed as Entyvio, vedolizumab is approved for adults with moderately to severely active
Agamree is a new drug that operates by attaching to the same receptor as glucocorticoids while altering its downstream activity. The agreement involves the development, manufacturing and commercialisation
The approval offers healthcare providers with an additional option alongside the existing 1g version. The new kit contains 100ml Water for Infusion (WFI) and includes the nextaro reconstitution
The tender offer expired on 5 January 2026. The transaction involved purchasing all outstanding shares of Mersana at $25 per share in cash, along with one non-tradable contingent
The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people. CK0804 is an
The approval applies to patients whose disease is metastatic or locally advanced, or where surgery may cause morbidity, and who have progressed on prior therapies or lack satisfactory
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.